In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more

A 27-year-old Caucasian male professional rugby player with signs of decompensated heart failure

Sabiha Gati, Sports Cardiology Quiz Section Editor

Rehabilitation and Sports Cardiology
Prevention


The case

A 27-year-old Caucasian male professional rugby player was admitted to his local district general hospital with signs and symptoms of decompensated heart failure.

He admitted to regularly taking cocaine and performance enhancing steroids. He had no other significant past medical history.

  • His ECG showed atrial fibrillation (AF), (Figure 1).
  • A transthoracic echocardiogram revealed bi-atrial dilatation and a dilated left ventricle (LV) with moderate to severe LV systolic dysfunction.
  • He was acutely managed with intravenous diuretics and initiated on evidence-based heart failure medications including beta-blockers and angiotensin converting enzyme (ACE) inhibitors.
  • Once stabilised he was discharged on bisoprolol 2.5 mg, ramipril 5 mg and rivaroxaban, a non-vitamin K antagonist.

In view of his drug history a diagnosis of drug-induced dilated cardiomyopathy (DCM) was made.

Figure 1: Admission ECG showing atrial fibrillation

Figure 1: Admission ECG showing atrial fibrillation

 

 

Test your knowledge

 

Case report

Read also the corresponding case report:

"Game changer? A sporting indication to implant a left atrial appendage closure device in a rugby player with atrial fibrillation: A case report" by Andre Briosa e Gala, Andrew Cox, Michael Pope and Timothy R Betts
European Heart Journal - Case Reports, doi:10.1093/ehjcr/ytz242

Interested in learning more? Access the ESC e-Learning Platform and discover the EAPC Sports Cardiology online courses. 

EAPC online educational courses are only accessible to EAPC Ivory, Silver and Gold Members. Not yet an EAPC Member? 

Join now

Note: The views and opinions expressed on this page are those of the author and may not be accepted by others. While every attempt is made to keep the information up to date, there is always going to be a lag in updating information. The reader is encouraged to read this in conjunction with appropriate ESC Guidelines. The material on this page is for educational purposes and is not for use as a definitive management strategy in the care of patients. Quiz material in the site are only examples and do not guarantee outcomes from formal examinations.

References

1. Kotecha, D. and J.P. Piccini, Atrial fibrillation in heart failure: what should we do? European Heart Journal, 2015. 36(46): p. 3250-3257.1. Kotecha, D. and J.P. Piccini, Atrial fibrillation in heart failure: what should we do? European Heart Journal, 2015. 36(46): p. 3250-3257.

2. Kirchhof, P., et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J, 2016. 37(38): p. 2893-2962.

3. Echt, D.S., et al., Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med, 1991. 324(12): p. 781-8.

4. Zipes, D.P., et al., Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol, 2015. 66(21): p. 2412-2423.

5. Pelliccia, A., et al., Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J, 2019. 40(1): p. 19-33.

6. Holmes, D.R., Jr., M. Alkhouli, and V. Reddy, Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation. Mayo Clin Proc, 2019. 94(5): p. 864-874.

7. Sharma, S.P., P. Park, and D. Lakkireddy, Left Atrial Appendages Occlusion: Current Status and Prospective. Korean Circ J, 2018. 48(8): p. 692-704.

8. Reddy, V.Y., et al., Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation, 2013. 127(6): p. 720-9.

9. Holmes, D.R., Jr., et al., Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol, 2014. 64(1): p. 1-12.

10. Holmes, D.R., Jr., et al., Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol, 2015. 65(24): p. 2614-2623.

Notes to editor

Authors information:

Dr. Andre Briosa e Gala, Oxford University Hospital NHS Foundation Trust
Dr. Andrew Cox, Oxford University Hospital NHS Foundation Trust
Dr. Tim Betts, Oxford University Hospital NHS Foundation Trust